ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Cambrex is expanding its large-scale active pharmaceutical ingredient operation in Karlskoga, Sweden, introducing continuous-flow production of high-purity drug intermediates. The expansion will also add multipurpose batch reactors ranging from 4 to 12 m3, a 9-m3 hydrogenation reactor, and an upgraded control room. Work on the project is set to be completed later this year.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X